• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过供体来源的宿主非反应性体外诱导的中枢记忆 CD8 T 细胞诱导骨髓同种异体移植物的耐受。

Induction of tolerance to bone marrow allografts by donor-derived host nonreactive ex vivo-induced central memory CD8 T cells.

机构信息

Department of Immunology, Weizmann Institute of Science, Rehovot 76100, Israel.

出版信息

Blood. 2010 Mar 11;115(10):2095-104. doi: 10.1182/blood-2009-10-248716. Epub 2009 Dec 30.

DOI:10.1182/blood-2009-10-248716
PMID:20042725
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2837324/
Abstract

Enabling engraftment of allogeneic T cell-depleted bone marrow (TDBM) under reduced-intensity conditioning represents a major challenge in bone marrow transplantation (BMT). Anti-third-party cytotoxic T lymphocytes (CTLs) were previously shown to be endowed with marked ability to delete host antidonor T cells in vitro, but were found to be less effective in vivo. This could result from diminished lymph node (LN) homing caused by the prolonged activation, which induces a CD44(+)CD62L(-) effector phenotype, and thereby prevents effective colocalization with, and neutralization of, alloreactive host T cells (HTCs). In the present study, LN homing, determined by imaging, was enhanced upon culture conditions that favor the acquisition of CD44(+)CD62L(+) central memory cell (Tcm) phenotype by anti-third-party CD8(+) cells. These Tcm-like cells displayed strong proliferation and prolonged persistence in BM transplant recipients. Importantly, adoptively transferred HTCs bearing a transgenic T-cell receptor (TCR) with antidonor specificity were efficiently deleted only by donor-type Tcms. All these attributes were found to be associated with improved efficacy in overcoming T cell-mediated rejection of TDBM, thereby enabling high survival rate and long-term donor chimerism, without causing graft-versus-host disease. In conclusion, anti-third-party Tcms, which home to recipient LNs and effectively delete antidonor T cells, could provide an effective and novel tool for overcoming rejection of BM allografts.

摘要

在低强度预处理条件下实现异基因 T 细胞耗竭骨髓(TDBM)的植入是骨髓移植(BMT)中的一个主要挑战。先前的研究表明,抗第三方细胞毒性 T 淋巴细胞(CTLs)具有显著的体外删除宿主抗供体 T 细胞的能力,但在体内效果较差。这可能是由于延长的激活导致淋巴结(LN)归巢减少所致,这种激活导致 CD44(+)CD62L(-)效应表型,从而阻止与同种反应性宿主 T 细胞(HTCs)的有效共定位和中和。在本研究中,通过成像确定 LN 归巢,通过有利于抗第三方 CD8(+)细胞获得 CD44(+)CD62L(+)中央记忆细胞(Tcm)表型的培养条件得到增强。这些 Tcm 样细胞在 BM 移植受者中表现出强烈的增殖和持久的持久性。重要的是,只有供体型 Tcms 才能有效地删除携带抗供体特异性 T 细胞受体(TCR)的同种异体 HTCs。所有这些特性都与提高克服 T 细胞介导的 TDBM 排斥反应的疗效有关,从而实现高存活率和长期供体嵌合,而不会引起移植物抗宿主病。总之,归巢到受者 LN 并有效删除抗供体 T 细胞的抗第三方 Tcms 可以为克服 BM 同种异体移植物排斥反应提供一种有效且新颖的工具。

相似文献

1
Induction of tolerance to bone marrow allografts by donor-derived host nonreactive ex vivo-induced central memory CD8 T cells.通过供体来源的宿主非反应性体外诱导的中枢记忆 CD8 T 细胞诱导骨髓同种异体移植物的耐受。
Blood. 2010 Mar 11;115(10):2095-104. doi: 10.1182/blood-2009-10-248716. Epub 2009 Dec 30.
2
Murine anti-third-party central-memory CD8(+) T cells promote hematopoietic chimerism under mild conditioning: lymph-node sequestration and deletion of anti-donor T cells.小鼠抗第三方中央记忆 CD8(+) T 细胞在轻度调理条件下促进造血嵌合体形成:淋巴结隔离和抗供体 T 细胞的删除。
Blood. 2013 Feb 14;121(7):1220-8. doi: 10.1182/blood-2012-07-441493. Epub 2012 Dec 5.
3
Induction of transplantation tolerance in haploidenical transplantation under reduced intensity conditioning: the role of ex-vivo generated donor CD8+ T cells with central memory phenotype.在低强度预处理的半相合移植中诱导移植耐受:体外生成具有中央记忆表型的供体 CD8+T 细胞的作用。
Best Pract Res Clin Haematol. 2011 Sep;24(3):393-401. doi: 10.1016/j.beha.2011.05.007. Epub 2011 Jul 13.
4
A new approach for eradication of residual lymphoma cells by host nonreactive anti-third-party central memory CD8 T cells.通过宿主非反应性抗第三方中央记忆 CD8 T 细胞清除残留淋巴瘤细胞的新方法。
Blood. 2013 Apr 11;121(15):3033-40. doi: 10.1182/blood-2012-06-432443. Epub 2013 Feb 27.
5
Influence of the additional injection of host-type bone marrow on the immune tolerance of minor antigen-mismatched chimeras: possible involvement of double-negative (natural killer) T cells.宿主型骨髓额外注射对次要抗原错配嵌合体免疫耐受的影响:双阴性(自然杀伤)T细胞的可能参与
Transplantation. 1999 Nov 27;68(10):1560-7. doi: 10.1097/00007890-199911270-00021.
6
Alloreactive memory T cells are responsible for the persistence of graft-versus-host disease.同种异体反应性记忆T细胞是移植物抗宿主病持续存在的原因。
J Immunol. 2005 Mar 1;174(5):3051-8. doi: 10.4049/jimmunol.174.5.3051.
7
Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necrosis factor family effector pathways.源自宿主CD8记忆T细胞的效应细胞介导对次要组织相容性抗原错配的同种异体骨髓移植的快速抗性,且无需穿孔素、Fas配体参与,同时抑制3种肿瘤坏死因子家族效应途径。
Biol Blood Marrow Transplant. 2005 Aug;11(8):576-86. doi: 10.1016/j.bbmt.2005.05.006.
8
Tolerance induction in presensitized bone marrow recipients by veto CTLs: effective deletion of host anti-donor memory effector cells.通过否决性细胞毒性T淋巴细胞在预先致敏的骨髓受体中诱导耐受:有效清除宿主抗供体记忆效应细胞。
J Immunol. 2007 Nov 15;179(10):6389-94. doi: 10.4049/jimmunol.179.10.6389.
9
Methyl-Guanine-Methyl-Transferase Transgenic Bone Marrow Transplantation Allows N,N-bis(2-chloroethyl)-Nitrosourea Driven Donor Mixed-Chimerism Without Graft-Versus-Host Disease, and With Donor-Specific Allograft Tolerance.甲基鸟嘌呤甲基转移酶转基因骨髓移植允许 N,N-双(2-氯乙基)-亚硝脲驱动的供体混合嵌合体而无移植物抗宿主病,并具有供体特异性同种异体移植耐受。
Transplantation. 2015 Dec;99(12):2476-84. doi: 10.1097/TP.0000000000000825.
10
Apoptotic donor leukocytes limit mixed-chimerism induced by CD40-CD154 blockade in allogeneic bone marrow transplantation.凋亡的供体白细胞限制了同种异体骨髓移植中CD40 - CD154阻断诱导的混合嵌合现象。
Biol Blood Marrow Transplant. 2006 Dec;12(12):1239-49. doi: 10.1016/j.bbmt.2006.08.038.

引用本文的文献

1
Anti-viral CD8 central memory veto cells as a new platform for CAR T cell therapy.抗病毒CD8中枢记忆否决细胞作为嵌合抗原受体T细胞疗法的新平台
Stem Cells Transl Med. 2025 May 31;14(6). doi: 10.1093/stcltm/szaf020.
2
Correction of T-Cell Repertoire and Autoimmune Diabetes in NOD Mice by Non-myeloablative T-Cell Depleted Allogeneic HSCT.非清髓性 T 细胞清除的同种异体 HSCT 纠正 NOD 小鼠的 T 细胞库和自身免疫性糖尿病。
Stem Cells Transl Med. 2023 May 15;12(5):281-292. doi: 10.1093/stcltm/szad021.
3
Correction of murine sickle cell disease by allogeneic haematopoietic cell transplantation with anti-3rd party veto cells.通过使用抗第三方否决细胞的同种异体造血细胞移植纠正小鼠镰状细胞病。
Bone Marrow Transplant. 2021 Aug;56(8):1818-1827. doi: 10.1038/s41409-021-01237-6. Epub 2021 Mar 3.
4
A strategy to protect off-the-shelf cell therapy products using virus-specific T-cells engineered to eliminate alloreactive T-cells.利用经过基因工程改造以消除同种异体反应性 T 细胞的病毒特异性 T 细胞来保护现成的细胞治疗产品的策略。
J Transl Med. 2019 Jul 24;17(1):240. doi: 10.1186/s12967-019-1988-y.
5
Towards 'off-the-shelf' genetically modified T cells: prolonging functional engraftment in mice by CD8 veto T cells.迈向“现成的”转基因T细胞:通过CD8否决性T细胞延长小鼠体内的功能性植入。
Leukemia. 2018 Apr;32(4):1039-1041. doi: 10.1038/leu.2017.332. Epub 2017 Nov 20.
6
Xenotransplantation: Where Are We with Potential Kidney Recipients? Recent Progress and Potential Future Clinical Trials.异种移植:潜在肾移植受者的现状如何?近期进展及潜在的未来临床试验
Curr Transplant Rep. 2017 Jun;4(2):101-109. doi: 10.1007/s40472-017-0149-6. Epub 2017 May 8.
7
The role of donor-derived veto cells in nonmyeloablative haploidentical HSCT.供体来源的否决细胞在非清髓性单倍型相合造血干细胞移植中的作用。
Bone Marrow Transplant. 2015 Jun;50 Suppl 2:S14-20. doi: 10.1038/bmt.2015.89.
8
5-azacytidine promotes an inhibitory T-cell phenotype and impairs immune mediated antileukemic activity.5-氮杂胞苷可促进抑制性T细胞表型并损害免疫介导的抗白血病活性。
Mediators Inflamm. 2014;2014:418292. doi: 10.1155/2014/418292. Epub 2014 Mar 13.
9
Haploidentical SCT: the mechanisms underlying the crossing of HLA barriers.单倍型相合造血干细胞移植:跨越HLA屏障的潜在机制。
Bone Marrow Transplant. 2014 Jul;49(7):873-9. doi: 10.1038/bmt.2014.19. Epub 2014 Feb 24.
10
A new approach for eradication of residual lymphoma cells by host nonreactive anti-third-party central memory CD8 T cells.通过宿主非反应性抗第三方中央记忆 CD8 T 细胞清除残留淋巴瘤细胞的新方法。
Blood. 2013 Apr 11;121(15):3033-40. doi: 10.1182/blood-2012-06-432443. Epub 2013 Feb 27.

本文引用的文献

1
Induction of tolerance in organ recipients by hematopoietic stem cell transplantation.造血干细胞移植诱导器官受体的免疫耐受
Int Immunopharmacol. 2009 Jun;9(6):694-700. doi: 10.1016/j.intimp.2008.12.009. Epub 2009 Jan 16.
2
IL-7 and IL-15 allow the generation of suicide gene-modified alloreactive self-renewing central memory human T lymphocytes.白细胞介素-7和白细胞介素-15可促使产生经自杀基因修饰的同种异体反应性自我更新的中枢记忆性人类T淋巴细胞。
Blood. 2009 Jan 29;113(5):1006-15. doi: 10.1182/blood-2008-05-156059. Epub 2008 Oct 31.
3
Efficacy of IL-2- versus IL-15-stimulated CD8 T cells in adoptive immunotherapy.白细胞介素-2刺激与白细胞介素-15刺激的CD8 T细胞在过继性免疫治疗中的疗效
Eur J Immunol. 2008 Oct;38(10):2874-85. doi: 10.1002/eji.200838426.
4
Tolerance and chimerism after renal and hematopoietic-cell transplantation.肾移植和造血细胞移植后的耐受性与嵌合现象。
N Engl J Med. 2008 Jan 24;358(4):362-8. doi: 10.1056/NEJMoa074191.
5
Bystander central memory but not effector memory CD8+ T cells suppress allograft rejection.旁观者中央记忆性而非效应记忆性CD8 + T细胞抑制同种异体移植排斥反应。
J Immunol. 2008 Jan 1;180(1):113-21. doi: 10.4049/jimmunol.180.1.113.
6
Photodynamic purging of alloreactive T cells for adoptive immunotherapy after haploidentical stem cell transplantation.单倍体相合干细胞移植后用于过继性免疫治疗的光动力清除同种反应性T细胞
Blood Cells Mol Dis. 2008 Jan-Feb;40(1):76-83. doi: 10.1016/j.bcmd.2007.06.022. Epub 2007 Nov 5.
7
Rapamycin prolongs susceptibility of responding T cells to tolerance induction by CD8+ veto cells.
Transplantation. 2006 Jan 15;81(1):88-94. doi: 10.1097/01.tp.0000185302.38890.6b.
8
Immune cell migration in inflammation: present and future therapeutic targets.炎症中的免疫细胞迁移:当前及未来的治疗靶点
Nat Immunol. 2005 Dec;6(12):1182-90. doi: 10.1038/ni1275.
9
Molecular signatures distinguish human central memory from effector memory CD8 T cell subsets.分子特征可区分人类中枢记忆性与效应记忆性CD8 T细胞亚群。
J Immunol. 2005 Nov 1;175(9):5895-903. doi: 10.4049/jimmunol.175.9.5895.
10
Cytokine signals in T-cell homeostasis.T细胞稳态中的细胞因子信号
J Immunother. 2005 Jul-Aug;28(4):289-94. doi: 10.1097/01.cji.0000165356.03924.e7.